Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Inclusion Criteria:

* 19 year old ≤ Male or female \< 85 year old
* Subject who underwent Endoscopic Submucosal Dissection for Gastric Adenoma or Early Gastric Cancer
* Subject who agrees to participate and spontaneously sign the Informed consent form(ICF).

Exclusion Criteria:

* Known hypersensitivity to any component of ilaprazole
* Subjects who are taking contraindicated medications(ex. atazanavir) for experimental and concomitant drug.
* Subjects with abnormal levels in the laboratory tests

  * Total Bilirubin, Creatinine\> 1.5 times upper limit of normal
  * Alanine transaminase(ALT), Aspartate transaminase(AST), Alkaline phosphatase, Blood urea nitrogen(BUN)\> 2 times upper limit of normal
* Subjects diagnosed with other cancer within 5 years other than stomach cancer.
* Subjects with a history of Zollinger-Ellison syndrome, Barrett's esophagus, primary esophageal motility abnormality, esophageal strictures, pancreatitis, malabsorption, severe cardiovascular or pulmonary disease
* Subjects with a history of major surgery that can affect gastric acid secretion.
* Subjects should continue taking the following medicine during the study period : anticholinergics, promoting motility agents, prostaglandin analogs, sucralfate, aspirin, steroid, NSAIDs drug
* Subjects with uncontrolled organ failure (liver dysfunction, renal dysfunction)
* Pregnant and/or lactating women
* Subjects participating in a clinical trial before another trial within 30 days
* Inconsistency judged subject by researcher